

Philip F Hughes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3457121/publications.pdf>

Version: 2024-02-01

35
papers

1,131
citations

430874

18
h-index

434195

31
g-index

36
all docs

36
docs citations

36
times ranked

1822
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of ectopic heat shock protein 90 in male and female primary afferent nociceptors regulates inflammatory pain. <i>Pain</i> , 2022, 163, 1091-1101.	4.2	2
2	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 217-226.	4.1	2
3	Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis. <i>ACS Chemical Biology</i> , 2022, 17, 536-544.	3.4	10
4	Understanding the sources of errors in ex vivo Hsp90 molecular imaging for rapid-on-site breast cancer diagnosis. <i>Biomedical Optics Express</i> , 2021, 12, 2299.	2.9	3
5	Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. <i>iScience</i> , 2021, 24, 103412.	4.1	20
6	A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. <i>Journal of Biological Chemistry</i> , 2020, 295, 1565-1574.	3.4	17
7	Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	36
8	Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. <i>Communications Biology</i> , 2020, 3, 226.	4.4	18
9	TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades. <i>Oncotarget</i> , 2020, 11, 1961-1970.	1.8	8
10	Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer. <i>Scientific Reports</i> , 2019, 9, 3461.	3.3	11
11	Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. <i>Arthritis Research and Therapy</i> , 2019, 21, 292.	3.5	31
12	Application of immobilized ATP to the study of NLRP inflammasomes. <i>Archives of Biochemistry and Biophysics</i> , 2019, 670, 104-115.	3.0	13
13	Synergistic role of HSP90 ¹ and HSP90 ² to promote myofibroblast persistence in lung fibrosis. <i>European Respiratory Journal</i> , 2018, 51, 1700386.	6.7	41
14	Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	27
15	Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. <i>Scientific Reports</i> , 2018, 8, 17058.	3.3	27
16	Targeting Pim Kinases and DAPK3 to Control Hypertension. <i>Cell Chemical Biology</i> , 2018, 25, 1195-1207.e32.	5.2	21
17	Optimizing fluorescently-tethered Hsp90 inhibitor dose for maximal specific uptake by breast tumors. , 2018, , .		1
18	A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy <i>in Vivo</i> . <i>ACS Chemical Biology</i> , 2017, 12, 1047-1055.	3.4	40

#	ARTICLE	IF	CITATIONS
19	<i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. <i>Clinical Cancer Research</i> , 2017, 23, 7531-7542.	7.0	15
20	Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF- α Inhibition for Cancer and Autoimmune Disease. <i>Cell Chemical Biology</i> , 2017, 24, 1029-1039.e7.	5.2	104
21	Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens. <i>Scientific Reports</i> , 2017, 7, 17487.	3.3	15
22	Cellular fatty acid synthase is required for late stages of HIV-1 replication. <i>Retrovirology</i> , 2017, 14, 45.	2.0	36
23	Abstract 1859: Hsp90 targeted near infrared molecular imaging to detect mammographically occult invasive lobular breast cancer. , 2017, , .		0
24	An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target. <i>Antiviral Research</i> , 2016, 130, 81-92.	4.1	42
25	The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. <i>Nature Communications</i> , 2016, 7, 12037.	12.8	56
26	Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2 + Breast Cancer. <i>Cell Chemical Biology</i> , 2016, 23, 678-688.	5.2	109
27	Abstract 4457: Novel fatty-acid synthase inhibitor in combination with platinum-based therapy provides increased tumor killing efficacy in luminal breast murine model. , 2015, , .		0
28	Abstract 2703: Overcoming Lapatinib resistance by the fatty acid synthase inhibitor HS-106. , 2015, , .		0
29	Identification of an Allosteric Small-Molecule Inhibitor Selective for the Inducible Form of Heat Shock Protein 70. <i>Chemistry and Biology</i> , 2014, 21, 1648-1659.	6.0	54
30	Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells. <i>Chemistry and Biology</i> , 2013, 20, 1187-1197.	6.0	43
31	Fluorescence Linked Enzyme Chemoproteomic Strategy for Discovery of a Potent and Selective DAPK1 and ZIPK Inhibitor. <i>ACS Chemical Biology</i> , 2013, 8, 2715-2723.	3.4	41
32	A highly selective Hsp90 affinity chromatography resin with a cleavable linker. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3298-3305.	3.0	26
33	Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2550-2554.	2.2	12
34	Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90. <i>Chemistry and Biology</i> , 2010, 17, 686-694.	6.0	79
35	Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4288-4305.	6.4	170